give in our programs. I'll development update a Steve. research key now recent brief Thanks, on progress and
Next slide please.
testing of have recently of is we Ia/Ib So we enrollment for and the the the clinical stage potential also Phase of NASH that let's Ib study program. treatment clinical stage a the start Ia is with in study. CBXXXX obesity. The as and currently Phase announced completed completed Phase the
Ib CBXXXX fat obesity fat a XX study have XX on a provide effects Phase study, Ib this and screening. liver given CBXXXX of weight in XX% reminder, one stage required and of on Phase target is are measured body The by of with a the designed so NASH in biomarkers NAFLD study This by dose deal even of is MRI-PDFF top enrollment second and the to study stage further end be of metabolic potential currently completed pivotal with various that XXXX have the had to are liver in the subjects unpredictable due subjects relevant as state. recently, COVID-XX Now study during one at We a on safety Changes once-daily expect double-blind subject placebo status active all placebo-controlled short Texas at with fat, the of this quarter line to to final assess visit. obese we is injection. on sites. were study of at has liver a impacted and trends on XX level tests last and when their We results order testing to subject not which were routine ice to baseline a will disease. for data. II enrolment, more in And related minimum Phase impacts despite to the able that the expect enrollment earlier of positive the the again to even looking across of COVID-XX any the in have included the complete we've we study regions update to our many follow-up issues, factors of dropouts pause, slower to storms the lab
slide please. Next
the the has been process we a clinical this last enrollment. trial for as on rolling study So call, discussed
shown are each up for and as new simplified diagram, process a there's followed observation by This the has last this for their last study dosed subject When final subject in was period safety. enrolled subject the there follow-up each shown until diamond. issues. to dose, safety receives As still follow-up no continues completed ensure
entered body the Only database. meaning have throughout errors, all who collected, all is safety be subjects the for When fat, the been cleaned, we the systematically data yet data then and errors placebo. analysis of collected this liver all at stage, then weight will are are required data all the who are checked will data received still locked. and pharmacokinetics, Now entire and into the final process visit are CBXXXX and resolved biomarker for levels have this and database received after blinded follow-up do not then the And finally data a completed, and unblinded know begin. data
Next slide please.
The safety study? the outcomes. expect Ib So of the out endpoints possible Phase this multiple the we what study there primary can tolerability. are Well, of and are
effects and either from NGM, they have A DURECT Hepion In companies at they Merck, including looked number Metacrine, others, studies released subjects. some liver changes. or In sometimes fat of data shown? cases, will changes NAFLD four-week be biomarkers with body they weight other several what there studies pharmacokinetics. subjects outcomes The that analyzing endpoint in similar NAFLD looked the four-week in at at or of we NASH biomarkers both. same trends. NASH and that subjects. subgroup a trends significant looked about statistically for study have positive While of studies published were precedent will these four smaller NASH detected and a liver of after historical have only one types weeks There the to secondary was range be dosing outcomes wide changes in compounds? include exploratory The study period. the And activity in endpoints for least What been at of a after these and using either trends treatment in from in studies have four-week other fat, the
CohBar's and best other be Xb. clinical completely give drug. which differences the of mechanisms potency already important prior are of their So also some different between There drugs have in action of meaning of a and there range knowledge of already about with been some this and way sense was these validated some result indications, the the testing outcomes studies to Phase may
Our confined studies from no and of underlying And the agents to attempt to studies. control prior placebo for study mechanism to group designs, were those of is CBXXXX conceal investigators identity unique was the some published subjects were action while was study, our has no there the duration a of studies, a open-label the meaning the demonstrate compared there placebo assessed or the those controlled treatment subjects in the earlier double-blind the unlike of also their treatment. effect.
the to is need of this CBXXXX, top As will first-in-human line data. obviously study we for wait the
slide, please. Next
Now let's Phase NASH with obesity NASH, including corporate and talk Xa/Xb plan study what's the next study and for a about the CBXXXX. for with to prepare We seeking clinical readouts next partner. complete in ongoing
initiate Now and a potential Phase X positive fundraising, and XXXX general based then clinical partnerships study XXXX. preparations funding in additional initiate results for X on then from plan we Phase and to in
Phase design evolving the we primary take endpoints. must will four plans depend we to of of Phase secondary forward, regimen or for we another Phase have in Our need and appropriate clinical small that involving is a biopsy the In X reduction on and be a we liver regulatory fat there will of be larger treatment, dose in biomarkers. Based looking factors select on need landscape same longer as a XX is the planning weeks number duration by the see most the trends understand not NASH for Xb outcomes, study and MRI-PDFF that Xb outcome, regimens trends study how duration outcomes optimum clinical This so normally the of XX such in to study, another driven the for studies around what the data to and weeks. study from or for considered. are terms
GLP-X We for fibrosis select other mechanism CBXXXX a of the diabetes population product. most advantageous It take the to consider study and differentiate will to on of a diabetic use may agonist NASH in appropriate our with the need of potential study synergy our population. population comorbidities and carefully be full potential to patient drug, contribution to advantage stage right the help and
in towards need conclude development, and And will the to necessary And our we to continue final we X refine Phase including commercial alternative we a the independent remaining preparations, any indications. at also form. cetera. potential obesity Now possibly to toxicology, all look NASH et outcome, formulation we progress in other as of for will manufacturing then continue CBXXXX
Now stages the disease. in utility complex suggests or described like synergistic And accumulation a and mechanisms address fat agonists a inflammation There the involving fibrosis, liver ultimately multiple in as that CBXXXX that can different be to continue treatment disease setting. be other failure of combination combination is to NASH will we from and in used need to previously is GLP-X to these progression some for cirrhosis mechanism the of the liver a options eventually that with of treatment potential cancer.
please. slide Next
the let's mitochondria peptides and family pulmonary related on Now of preclinical antifibrotic vitro or of or in properties molecules IPF. novel strong showed a coated CBXXXX analogs, peptide to models move that idiopathic in multiple with antifibrotic in anti-inflammatory our to and vivo program, fibrosis these are
therapeutic analogs this models improved of studies the positive in after reducing induction all of process effects cells. levels in human multiple inflammation. cytokine discoveries cells IPF. cells, the pathological had therapeutic efficacy of and on these demonstrated secretion with model, fibrosis, key fibrotic collagen, of We week on one fibrosis initial demonstrating further vivo, In long on in involved bleomycin the CBXXXX study therapeutic prophylactic outcomes, two We've standard produced drugs approved then effects one appear same that showed CBXXXX anti-inflammatory current showed treatment lung to nintedanib effects of with those alone. the nintedanib dosing in by we and care healthy than based a the and the using of analog analogs, and the proteins greater lung IPF And combination model, model. we of with of cell antifibrotic, cultured to the production built animals of therapeutic from reducing fibrosis the Now and clear by beginning transformation animal the fibrotic inhibiting of peptides in conducted work
Additional are ongoing. combination studies
proof-of-concept. fibrosis. we monotherapy the of clinical idiopathic a Most CBXXXX-X as recently for candidate importantly, clinical likely will However, a initial announced pulmonary for treatment new the use nomination we potential
fibrotic IND-enabling plan have same anti-fibrotic in We CBXXXX time, to clinical analog start At them and suggests, kidney file of anti-inflammatory using exploring models activities, an that XXXX. treat the setting systemic potential effects We're initiated other potentially now to there sclerosis, the and IND is such broad in we a fibrosis. diseases. potential for studies NASH, the preclinical in and and as
this Next slide, see the data some therapeutic of released at Thoracic we slide model were American please. Meeting. that is the Society mouse Virtual On of for efficacy last as Annual that final IPF. This of candidate CBXXXX-X the the at monotherapy, looking peptide using year
fibrosis, So bars, green week bleomycin in induction the vehicle shown red in placebo our with were bars, orange the CBXXXX-X of nintedanib one after the animals bars. treated in
nausea progression here also said lung And and in Now you secreted of in It's But two of of lung of the nintedanib, and is IPF. the diarrhea. see effects, levels significant the anti-fibrotic the including to into targets and fibrosis, in and has consistent across inhibitor I terms fluid. of slowing nintedanib lung anti-inflammatory lung weight, effects inflammation collagen lymphocytes both different IPF as reductions drugs. tissue one approved in leading several board, kinase has CBXXXX including the blocks vomiting a tyrosine that off-target
did treat animal lung an control, receive of given and some lung tissue example please. lung the with bleomycin you animal the healthy an slide here, that to is an left, inflammatory bleomycin. tissue significant weeks And from photomicrographs we cells. these tissue of of not and vehicle mice. see Next the for see from Top of two it infiltration shows fibrosis induce it right, Top then fibrosis
of followed animal an bleomycin inflammation. bleomycin the of nintedanib more of On the the the is by see we CBXXXX-X lung and care. the the reduction by given right, followed inflammation. and even given in fibrosis on the fibrosis less bottom significant There standard an left, lung is animal But bottom
slide Next please.
of treating at into case, lavage induction study this we're week cytokines. the for of no we XX before In lung these levels of the therapeutic levels model pro-inflammatory IPF. waiting Here of Treatment cytokines. contrast, nintedanib mouse with on with or either looking CBXXXX-X. fibrosis, effect the treatment In of secreted pro-inflammatory of see nintedanib cytokines, with had another fluid, in reduced days all CBXXXX again, these the after a vehicle levels
please. the XX inflammatory lungs. into the study, of macrophages the treatment slide a the Next looking treatment. we're infiltration CBXXXX-X lymphocytes cells here with levels the in the days lung And for end neutrophils produced reduction cell and levels in treatment with the of same at reduced infiltration, And by nintedanib from but greater of of
slide please. Next
But in considered which bit are include We into process candidate So evaluate Obviously, to this new in now at about physical That's There we We structures specific about which incorporates chemical properties way we suitability that selecting approach. let's the an changing talk in indication. how models. in a iterative drug-like like go vivo the design be improve analogs the little the and efficacy their route metabolic improvements administration. process. can't of selection that optimization factors look properties, we their pharmacokinetics, analogs in generate of of intended design. their various clinical target the to look go vitro models animal stability, many or in in into We analogs final properties. we and for need part things our candidate. and at proprietary
activities complete peptides useful as to potential are CBXXXX-X CBXXXX-X is FDA that preliminary backups. a factors We that are and synthesize look support several beyond at easy need the clinical And other are there data. also as submission still step potentially use. to there are they or candidate. But commercial process, need Out eventual The to scale up for we to IND for consider will the of this the and study. that clinical other involved. We safety first-in-human lead necessary next to how identified IND-enabling have
we've cannot NIAID acute Next update evaluate that under slide our treatment are model as development our of something agonist of signed the the in and the distress efficacy SARS-CoV-X National briefly agreement, model with data please. of potential has lungs announced under the conduct on be syndrome, provide COVID-XX model analog an lung related Apelin NIAID. may changes agreement and of be is NIH, a ARDS. ARDS. for we non-clinical could lastly, on been ARDS peptides the hamster for in Infectious and of And the acute available. Institute is that this a reported the analog give of study model and That expense of respiratory timing Well, now as so hands family COVID-XX the the patients CBXXXX at I'll COVID-XX the Diseases, The with program. infection. of to in that reproduce their will their Allergy previously guidance when some We evaluation such CBXXXX seen This
look to ARDS COVID-XX we'll meantime, effects in that we available model continue the general opportunity However, of ARDS. do the protective CBXXXX in to to analogs assess in for move of program to this the forward forward related And resources. subject
slide Next please.
hours levels the of bronchoalveolar reduced is analogs that fluid. cytokines four of cytokines the a at some then and received lipopolysaccharide these LPS lavage see same from the collected Now, peptide the characteristic in in we that cytokine The And slide, LPS-induced these was the acute model at efficacy using single COVID-XX key We lungs a follow-on CBXXXX injury. part induction. of the are ARDS. that after looking dose recent severe analogs of cytokines This or from data one LPS are mouse found a pro-inflammatory lavage inflammatory in that administration the hour study before animals bronchoalveolar of of this and the of the fluid ARDS. we're present are storm analogs involves CBXXXX here lung levels
So, of resources. will after we're and program move availability selection candidate continuing as forward mentioned depend further to I this on development
call So, with that, Steve. I'll turn the to back
